These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 12783603)

  • 1. Current and potential pharmacological treatments for obsessive-compulsive disorder.
    Davidson J; Bjorgvinsson T
    Expert Opin Investig Drugs; 2003 Jun; 12(6):993-1001. PubMed ID: 12783603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental therapeutics for refractory obsessive-compulsive disorder: translational approaches and new somatic developments.
    Berlin HA; Hamilton H; Hollander E
    Mt Sinai J Med; 2008; 75(3):174-203. PubMed ID: 18704978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity.
    Brakoulias V
    Expert Opin Pharmacother; 2014 Jul; 15(10):1321-3. PubMed ID: 24866422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of fluoxetine on various subtypes of obsessive-compulsive disorder.
    Farnam A; Goreishizadeh MA; Farhang S
    Arch Iran Med; 2008 Sep; 11(5):522-5. PubMed ID: 18759519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond depression: citalopram for obsessive-compulsive disorder.
    Pato MT
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 2():S19-26. PubMed ID: 10471169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case series: Adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive compulsive disorder.
    Owley T; Owley S; Leventhal B; Cook EH
    J Child Adolesc Psychopharmacol; 2002; 12(2):165-71. PubMed ID: 12188985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between obsessive-compulsive disorder and chaos.
    Kubota S; Sakai K
    Med Hypotheses; 2002 Jul; 59(1):16-23. PubMed ID: 12160676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroanatomical correlates of naturalistic long-term outcome of obsessive-compulsive disorder treated with selective serotonin reuptake inhibitors.
    Narayanaswamy JC; Kalmady SV; Cherian AV; Venkatasubramanian G; Reddy JY
    J Clin Psychopharmacol; 2014 Apr; 34(2):282-5. PubMed ID: 24525636
    [No Abstract]   [Full Text] [Related]  

  • 10. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic approaches to the treatment of refractory obsessive-compulsive disorder.
    Kochan LD; Qureshi AI; Fallon BA
    Curr Psychiatry Rep; 2000 Aug; 2(4):327-34. PubMed ID: 11122977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current issues in the pharmacologic management of obsessive compulsive disorder.
    Rasmussen SA; Eisen JL; Pato MT
    J Clin Psychiatry; 1993 Jun; 54 Suppl():4-9. PubMed ID: 8101187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pathogenesis and treatment of obsessive-compulsive disorder.
    Dolberg OT; Iancu I; Sasson Y; Zohar J
    Clin Neuropharmacol; 1996 Apr; 19(2):129-47. PubMed ID: 8777767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of pharmacologic treatments for obsessive-compulsive disorder.
    Kaplan A; Hollander E
    Psychiatr Serv; 2003 Aug; 54(8):1111-8. PubMed ID: 12883138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological management of obsessive-compulsive disorder: a review for clinicians.
    McDonough M; Kennedy N
    Harv Rev Psychiatry; 2002; 10(3):127-37. PubMed ID: 12023928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological treatments for obsessive-compulsive disorder and the serotonin-dopamine hypothesis].
    Okamoto Y
    Seishin Shinkeigaku Zasshi; 2011; 113(1):36-44. PubMed ID: 21404630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obsessive-compulsive spectrum disorders: effective treatment with paroxetine.
    Ravindran AV; Lapierre YD; Anisman H
    Can J Psychiatry; 1999 Oct; 44(8):805-7. PubMed ID: 10566112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder.
    Goddard AW; Shekhar A; Whiteman AF; McDougle CJ
    Drug Discov Today; 2008 Apr; 13(7-8):325-32. PubMed ID: 18405845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tourette syndrome. Medical and surgical treatment of obsessive-compulsive disorder.
    Rapoport JL; Inoff-Germain G
    Neurol Clin; 1997 May; 15(2):421-8. PubMed ID: 9115472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does melatonin mediate the therapeutic effects of 5-HT reuptake inhibitors in obsessive compulsive disorder?
    Sandyk R
    Int J Neurosci; 1992; 64(1-4):221-3. PubMed ID: 1342043
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.